Summary The fluorometric microculture cytotoxicity assay (FMCA) 
In vitro testing of chemotherapeutic drug combinations in acute myelocytic leukaemia using the fluorometric microculture cytotoxicity assay (FMCA) (AML) . A large heterogeneity with respect to cell kill was observed for all combinations tested, the interactions ranging from antagonistic to synergistic in terms of the multiplicative concept for drug interactions. However, an.'additive' model provided a significantly better fit of the data compared to the effect of the most active single agent of the combination (Dmax) for several common antileukaemic drug combinations. When the two interaction models were related to treatment outcome 38% of the non-responders showed preference for the additive model whereas the corresponding figure for responders was 80%. Overall, in 248 of 290 (85%) tests performed with drug combinations, there was an agreement between the effect of the combination and that of the most active single component. Direct comparison of Dmax and the combination for correlation with clinical outcome demonstrated only minor differences in the ability to predict drug resistance. The results show that FMCA appear to report drug interactions in samples from patients with AML in accordance with clinical experience. Furthermore, testing single agents as a substitute for drug combinations may be adequate for detection of clinical drug resistance to combination therapy in AML.
Chemotherapy for malignant disease has continuously improved over the past decades. At least part of this improvement can be attributed to the use of combination chemotherapy, perhaps most evident in the case of the leukaemias and the lymphomas (Rankin & Kaye, 1990 ).
Short-term in vitro drug sensitivity assays have raised the possibility of predicting clinical outcome and selecting optimal components for chemotherapeutic protocols for individual patients (Bosanquet, 1991; Kern & Weisenthal, 1990; Hongo et al., 1990; Larsson et al., 1992a; Pieters et al., 1991; Von Hoff, 1988; Weisenthal & Lippman, 1985) . Although the majority of patients are treated with drug combinations, these assays most commonly test single agents. For most solid tumours, the in vitro activity of the most active single drug measured by clonogenic (Sondak et al., 1988a) and thymidine assays (Sondak et al., 1988b) has been shown to closely predict the effect of combinations. However, for tumours where combination chemotherapy has been more successful (i.e. lymphomas and leukaemias) this may not be the case. Undetected interactions between drugs may thus constitute an important source of false negative test results of in vitro drug sensitivity assays.
We have previously described the fluorometric microculture cytotoxicity assay (FMCA) for drug sensitivity testing of cell lines and tumour cell samples from patients with acute myelocytic leukaemia (AML; Larsson et al., 1992a; Larsson & Nygren, 1990) . In the present study we employed this method for the study of drug interactions in AML. The results show a large variability with respect to the effects of different drug combinations ranging from antagonistic to synergistic. In contrast to observations made in solid tumours (Sondak et al., 1988a; Sondak et al., 1988b ) the effect of some clinically AML active combinations was more accurately predicted by an additive model of drug interactions. However, despite this, the test result of the most active single agent could correctly predict the in vitro activity of the combination in the majority of the cases.
Materials and methods

Leukaemic samples
Totally 44 leukaemic cell samples were obtained from peripheral blood or bone marrow from 40 adult patients with newly diagnosed or relapsed AML. Twenty-nine samples were from previously untreated patients and 15 were from previously treated patients. Mononuclear cells were obtained by 1,077 g ml-' Ficoll-Isopaque (Pharmacia, Uppsala, Sweden) density gradient centrifugation. Viability was determined by trypan blue exclusion test and the density gradient centrifugation generally yielded cell suspensions of >85% leukaemic cells as judged by May-Grunwald-Giemsa stained cytocentrifugate preparations. Culture medium RPMI 1640 medium (Flow, Herts, England) supplemented with 10% heat-inactivated foetal calf serum (FCS; Flow), 2 mM glutamine, 50 Lg ml' streptomycin and 60 tLg ml-' penicillin was used throughout. Cells were cryopreserved in culture medium containing 10% dimethyl sulfoxide (DMSO) and 50% FCS by initial freezing for 24 h in -70'C followed by storage in liquid nitrogen. Both fresh and cryopreserved samples were used in this study.
Reagents and drugs
Fluorescein diacetate (FDA; Sigma Chem Co, St. Louis, MO, USA) was dissolved in DMSO (Sigma) and kept frozen (-20'C) as a stock solution (10 mg ml-') protected from light. Drugs were obtained from various sources and were diluted and tested at the concentrations indicated in Table I . Empirically derived cut-off concentrations (EDCC) were selected according to principles described previously and are in most cases in the range achievable in plasma (Larsson et al., 1992a) . EDCC concentrations of each drug were used in the combinations (Table II) Table I. FMCA procedure The principal steps of the assay procedure have been described previously (Larsson et al., 1992a; Larsson & Nygren, 1990) . Day 1 180 pl of the leukaemia preparation at 2.5-5 x 10' cells ml-' in culture medium were seeded into the wells of V-shaped 96 well experimental microtiter plates (Nunc, Roskilde, Denmark) prepared as described above. Six blank wells received only culture medium and six wells with cells, but without drugs served as control. The culture plates were then incubated at 37C in humidified atmosphere containing 95% air and 5% CO2 for 72 h. At the end of the incubation period the plates were centrifuged (200 g, 7 min) and the medium removed by flicking the plate. After one wash with PBS, 200 pl of PBS containing FDA (10 ,l ml-') was added columnwise to control, experimental and blank wells. Subsequently the plates were incubated for 1 h before reading the fluorescence in a Fluoroscan 2. The fluorometer was blanked against wells containing PBS including the fluorescent dye but without cells. The results obtained by the indicator FDA are presented as survival index (SI) defined as fluorescence in per cent of control cultures (Indicator test/Indicator control, with blank values subtracted). Quality criteria for a successful assay included an FDA signal in control cultures of > 5 x mean blank values, mean CV in control cultures of <30% and >80% of leukaemic cells prior to incubation.
Models of drug interactions in vitro
Two models of combination chemotherapy were tested essentially according to the 'multiplicative' concept of drug interactions (Valeriote & Lin, 1975) and to the procedure and terminology used previously by Sondak et al. for in vitro testing of solid tumours (Sondak et al., 1988a) . The observed SI values of the combination were plotted against that predicted by two models. In the first model, termed 'additive', the effect of the combination is expected to be equal to the product of the effect of its constituents. Thus, a (Valeriote & Lin, 1975) . In some analysis of the data, the ratio of observed SI values and those expected according to the additive model was plotted and observed/ expected ratios 1 ± 0.2 were arbitrarily defined as additive interactions (Lepri et al., 1991) .
Statistical analysis
The two models were compared using the non-parametric sign test. For each sample tested, the absolute value (SIa) of (/SIa/) the difference between the observed effect of the drug combination (SI,bs) 
In vitro-in vivo comparison
Patients were treated according to local protocols without knowledge of assay results. In vivo response was defined as complete response (CR) as previously described (Larsson et al., 1992a) . The patients included for correlation were those receiving relevant combination therapy with curative intent and in which a clear documentation of clinical response were available. The single agent in vitro-in vivo comparisons were based on the sensitivity of the most active single agent actually given in vivo. Correlations were performed at a previously specified concentration producing a significant scatter of SI values (Larsson et al., 1992a) using either a fixed cut-off line (SI = 40%) determined from comparison with previous results using the differential staining cytotoxicity assay (Larsson et al., 1992b) or the use of drug specific relative cut-off lines (median and median + 1 standard deviation (s.d.; Kern & Weisenthal, 1990; Bosanquet, 1991 (Kern & Weisenthal, 1990; Bosanquet, 1991) .
Results
Effect of drug combinations
In Figure 1 the percentile distribution of SI values is shown for each drug (a) and the combinations investigated (b). Each bar encompasses 90% of the observations. The median is indicated by the solid line whereas the broken lines delimits 25% of the observations. The median value is lower for all combinations compared to the most active single component.
Type of interaction for different combinations
In Figure 2 the expected SI values are plotted against those observed for the AraC + Amsa and APV combinations. A large variability is not only noted between individual samples (Figure 2 ) but also observed for individual samples in response to different combinations (Figure 3 ). For AraC + Amsa the additive model provides a better distribution of points about the line of identity whereas the opposite is true for the APV combination. When the models were statistically compared using the sign test, the additive model provided a preferable fit for AraC + Amsa, MEA and AraC + Dnr (P<0.05; Table III ). The Dmax model was superior only in the case of APV (P <0.05) whereas no preference for either model was evident for the remaining combinations (nonsignificant; Table III ). In an attempt to investigate which of the individual components that contributed most to the efficacy of MEA, a second series of experiments (n = 14) was performed with seven two-drug combinations (Figure 3) . The results show that VP16 + Mit was the far most active twodrug combination in terms of additive and synergistic interactions (Figure 3 ). In eight out of 14 samples (57%) the interaction was synergistic compared to two of 14 (14%) and four of 14 (29%) for AraC + VP16 and AraC + Mit, respectively ( Figure 3 ).
Use of Dmax for prediction of combination activity
The accuracy of the most effective single agent in predicting the in vitro activity of the combination using an SI value of <40% as for separation of sensitive from resistant is shown in (Figure 4 , Table V) .
Discussion
The additive model was statistically preferable in three out of seven combinations tested by the sign test, including the Dnr + AraC, which is empirically known to be one of the clinically most active remission induction regimens (Marie & Zittoun, 1991) . For the APV combination, on the other hand, the Dmax model more closely predicted the effect. This is not surprising since Vcr and Pred has shown to be of little value for remission induction in AML (Goldman & James, 1990) and is only marginally active in vitro at concentrations which are clearly active in ALL (Larsson et al., 1992a) . Furthermore, when 6TG was added to an anthracycline + AraC containing regimen (DAT), no preference between the models was evident. This is compatible with the observation that no difference in terms of clinical CR rate at remission induction between AraC + anthracycline alone and the use of the same (Marie & Zittoun, 1991) . When the relationship to clinical outcome was investigated it became apparent that patients responding to therapy showed a higher preference for the additive model compared to Dmax whereas the opposite was true for patients not responding to therapy. The fact that nonresponders showed preference for the Dmax model is in accordance with the study of Sondak in which the majority of samples were from drug resistant tumours where activity and interactions of multiple drugs are expected to be at a minimum. The responding patient population, on the other hand, is drug sensitive and the probability for true drug interactions is consequently expected to be higher. However, one should also note that the frequency of additive interactions in the present study may (Valeriote & Lin, 1975 (Berenbaum, 1989 predicted the in vitro activity of the combination, based on a 40% SI cut-off limit for discriminating sensitive from resistant (Larsson et al., 1992b (Weisenthal & Kern, 1990; Bosanquet, 1991) . See Materials and methods. Overall response rate was 65%. activity of the most active single agent failed to predict the combination. The testing of combinations may thus be required in order to achieve maximal predictive accuracy.
However, comparison of direct clinical correlations based on combinations vs single agents showed no apparent advantage using the former approach. Although the tendency to produce false positive over false negative results varied in opposite directions for correlation procedures based on Dmax vs combination activity depending on which type of cut-off limit was used, the overall predictive ability was similar. Using the relative cut-off lines, the same EDR cases could be identified with both methods. It should be noted that 62% of the false negatives had SI values for most active single agent activity of < 50% suggesting that effective combinations requires active components. Additive and synergistic interactions may thus be more important for predictions of cure and survival than for predicting CR. This possibility is currently investigated.
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